Reaktionsgleichung
[N:1]1([C:7]2[N:8]=[C:9]3[NH:17][C@H:16]([C:18]([F:21])([F:20])[F:19])[CH2:15][CH2:14][N:10]3[C:11](=[O:13])[CH:12]=2)[CH2:6][CH2:5][O:4][CH2:3][CH2:2]1.I[C:23]1[CH:28]=[CH:27][C:26]([O:29][CH3:30])=[CH:25][CH:24]=1.COC1C2C(=C3C(=CC=2)C(OC)=CC=N3)N=CC=1>>[CH3:30][O:29][C:26]1[CH:27]=[CH:28][C:23]([N:17]2[C:9]3=[N:8][C:7]([N:1]4[CH2:6][CH2:5][O:4][CH2:3][CH2:2]4)=[CH:12][C:11](=[O:13])[N:10]3[CH2:14][CH2:15][C@H:16]2[C:18]([F:20])([F:21])[F:19])=[CH:24][CH:25]=1Komponenten
4
Edukt 3
Produkt 1
Versuchsvorschrift
The product is prepared according to the procedure described in Example 12, using 100 mg of (8S)-2-morpholin-4-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one (Example 1e), 108 mg of 1-iodo-4-methoxybenzene and 79 mg of 4,7-dimethoxy-1,10-phenanthroline. After purification by silica chromatography (eluent: CH2Cl2/MeOH 98/02), 31 mg of (8S)-9-(4-methoxyphenyl)-2-(morpholin-4-yl)-8-(trifluoromethyl)-6,7,8,9-tetrahydro-4H-pyrimido[1,2-a]pyrimidin-4-one are obtained in the form of a cream foam, the characteristics of which are the following:
Aufarbeitung
- customThe product is prepared
- customAfter purification by silica chromatography (eluent: CH2Cl2/MeOH 98/02), 31 mg of (8S)-9-(4-methoxyphenyl)-2-(morpholin-4-yl)-8-(trifluoromethyl)-6,7,8,9-tetrahydro-4H-pyrimido[1,2-a]pyrimidin-4-one
- customare obtained in the form of a cream foam
Quellen und Nachweise
- ORD-Eintrag
- ord-463898588958450c9854e4f6de4a561d
- Quelldatensatz
- uspto-grants-2014_09
- Patentnummer
- US08846670B2
Verknüpfte Notizen
Wird geladen…